DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich trimmed its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 3.1% in the fourth quarter, HoldingsChannel reports. The firm owned 46,169 shares of the medical device company’s stock after selling 1,485 shares during the period. Bank Julius Baer & Co. Ltd Zurich’s holdings in DexCom were worth $5,729,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Valley National Advisers Inc. boosted its stake in DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares during the period. MV Capital Management Inc. boosted its stake in DexCom by 99.3% during the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 138 shares during the period. Washington Trust Advisors Inc. boosted its stake in DexCom by 120.6% during the 4th quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock valued at $44,000 after purchasing an additional 193 shares during the period. NBC Securities Inc. acquired a new position in DexCom during the 3rd quarter valued at about $47,000. Finally, Thompson Siegel & Walmsley LLC acquired a new position in DexCom during the 3rd quarter valued at about $48,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity at DexCom

In related news, COO Jacob Steven Leach sold 14,639 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total value of $1,967,627.99. Following the completion of the sale, the chief operating officer now owns 273,913 shares in the company, valued at approximately $36,816,646.33. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other DexCom news, COO Jacob Steven Leach sold 14,639 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total value of $1,967,627.99. Following the completion of the sale, the chief operating officer now owns 273,913 shares in the company, valued at approximately $36,816,646.33. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Jereme M. Sylvain sold 3,363 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the sale, the chief financial officer now owns 71,142 shares of the company’s stock, valued at approximately $8,304,405.66. The disclosure for this sale can be found here. In the last 90 days, insiders sold 189,375 shares of company stock worth $25,530,859. 0.41% of the stock is owned by corporate insiders.

DexCom Stock Down 9.9 %

DXCM stock opened at $124.34 on Friday. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. The firm has a market cap of $49.24 billion, a PE ratio of 80.22, a P/E/G ratio of 2.37 and a beta of 1.20. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00. The firm has a 50 day simple moving average of $131.13 and a 200 day simple moving average of $118.30.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.27 by $0.05. The business had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.38%. Equities research analysts forecast that DexCom, Inc. will post 1.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Royal Bank of Canada initiated coverage on shares of DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 target price for the company. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Tuesday. UBS Group increased their price objective on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Canaccord Genuity Group increased their price objective on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a report on Friday. Finally, Citigroup increased their price objective on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Three analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average price target of $141.67.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.